Seer, Inc. (SEER)

Seer, Inc. (NASDAQ:SEER ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley.

REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.

Seer (SEER -2.83%), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period.

Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.35 per share a year ago.

Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Squarepoint Ops LLC reduced its position in shares of Seer, Inc. (NASDAQ:SEER – Free Report) by 46.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,156 shares of the company’s stock after selling 25,168 shares during the quarter. Squarepoint Ops LLC’s holdings in Seer were worth $67,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors also recently bought and sold shares of the company. Two Sigma Advisers LP increased its holdings in Seer by 24.2% during the 4th quarter. Two Sigma Advisers LP now owns 681,900 shares of the company’s stock worth $1,575,000 after purchasing an additional 132,800 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Seer in the fourth quarter worth approximately $114,000. Millennium Management LLC raised its stake in Seer by 9.1% in the fourth quarter. Millennium Management LLC now owns 615,812 shares of the company’s stock worth $1,423,000 after buying an additional 51,150 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Seer by 16.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 719,901 shares of the company’s stock worth $1,663,000 after buying an additional 103,630 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Seer by 17.6% in the fourth quarter. Bridgeway Capital Management LLC now owns 727,743 shares of the company’s stock worth $1,681,000 after buying an additional 109,000 shares in the last quarter. 75.20% of the stock is currently owned by hedge funds and other institutional investors. Seer Stock Up 1.4% Shares of NASDAQ:SEER opened at $2.23 on Wednesday. The company has a market capitalization of $131.28 million, a price-to-earnings ratio of -1.72 and a beta of 1.54. Seer, Inc. has a 52 week low of $1.56 and a 52 week high of $2.63. The firm has a 50 day moving average of $2.01 and a 200 day moving average of $2.15. Seer (NASDAQ:SEER – Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $3.25 million. Seer had a negative net margin of 565.83% and a negative return on equity of 21.96%. On average, sell-side analysts expect that Seer, Inc. will post -1.42 EPS for the current year. Seer Company Profile (Free Report) Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.

Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics.

Seer, Inc. (NASDAQ:SEER ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnings conference call.

Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.32 per share a year ago.

Revenue grew 37%, driven by increased product sales and service revenue Revenue grew 37%, driven by increased product sales and service revenue